Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Vinod Dasa

Orthopaedic Surgery Kenner, LA Medical Doctor

NPI 1215139431 CMS profile 145531

200 W Esplanade Ave, Suite 500, Kenner, LA 70065

Open in the dashboard

General payments

$1,880,614

1,342 records reported · program years 2019–2025

Research payments

$19,721

Paid to them · 5 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$35,391 paid to institutions, not to them · program years 2020–2022

Through program year 2025, Vinod Dasa of Kenner, LA is reported in the CMS Open Payments database as having received $1,880,614 across 1,342 general payments and $19,721 in research payments paid to them. Separately, studies naming them as principal investigator received $35,391 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

10 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $408,212 344
2024 General $282,218 217
2023 General $286,945 214
2022 General $279,980 212
2021 General $156,547 109
2021 Research $5,425 3
2020 General $149,932 80
2020 Research $12,448 1
2019 General $316,779 166
2019 Research $1,848 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Vinod Dasa
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Vinod Dasa were reported at $408,212. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Vinod Dasa Orthopaedic Surgery median Middle half National median
2019 $316,779 $644 $140–$2,844 $163
2020 $149,932 $312 $75–$1,860 $114
2021 $156,547 $520 $117–$2,495 $132
2022 $279,980 $598 $128–$2,731 $149
2023 $286,945 $461 $128–$2,264 $160
2024 $282,218 $497 $134–$2,475 $164
2025 $408,212 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pacira Pharmaceuticals Incorporated $943,504 553 payments
  2. Bioventus LLC $572,623 367 payments
  3. Vertex Pharmaceuticals Incorporated $149,128 122 payments
  4. Smith+Nephew, Inc. $76,474 84 payments
  5. Stryker Corporation $31,923 42 payments
  6. Sanara MedTech Inc. $27,056 25 payments
  7. Curonix LLC $21,150 25 payments
  8. Myoscience Inc. $20,206 19 payments
  9. Sanofi-Aventis U.S. LLC $10,221 6 payments
  10. Teleflex LLC $7,443 6 payments
  11. Other $20,886 93 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $803,602 230 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $531,712 83 payments
  3. Honoraria $191,663 32 payments
  4. Current or prospective ownership or investment interest $184,247 5 payments
  5. Travel and Lodging $139,289 506 payments
  6. Food and Beverage $30,094 485 payments
  7. Education $7 1 payment
Products named General payments · program years 2019–2025
  1. Iovera $432,570 347 payments
  2. Exparel Pain Management $364,900 210 payments
  3. Durolane Orthopedics/Orthopedic Surgery $187,880 81 payments
  4. Durolane Orthopedics/Orthopedic Surgery $170,178 120 payments
  5. EXPAREL Pain Management $141,017 24 payments
  6. iovera System $129,505 48 payments
  7. Zilretta Pain Management $97,243 54 payments
  8. JOURNAVX $91,723 90 payments
  9. Stimrouter Implantable Kit $70,768 49 payments
  10. Zilretta Pain Management $61,447 46 payments
  11. Other $203,267 279 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. CyMedica Orthopedics, Inc. $12,448 1 payment
  2. Bioventus LLC $5,425 3 payments
  3. Seikagaku Corporation $1,848 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

144

Median for Orthopedic Surgery: 203

Drug cost

$826

Median for Orthopedic Surgery: $1,433

Branded share of claims

0%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Diclofenac Sodium Generic 62 $547
Gabapentin Generic 31 $159
Cyclobenzaprine Hcl Generic 35 $73
Tramadol Hcl Generic 16 $47

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 15 billing codes

Paid by Medicare

$29,746

Medicare's payments for the services billed

Medicare patients

75

Average age 73

Services billed

363

48 women, 27 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 32%
Depression 28%
Ischemic heart disease 20%
Chronic kidney disease 19%
Osteoporosis 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Exparel
$69,504 — —
Zilretta
$21,191 — —
ZEPBOUND
$122 — —
APONVIE
$31 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

1,347 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record